The rail is live. The business is just starting.
ABDM went from concept to 500M records in 36 months. No country has moved health data interoperability this fast. But speed of infrastructure is not speed of adoption. A live rail is a starting point, not a finish line.
Think of China's health sector in 2008. Alipay and WeChat Pay existed as infrastructure. But the winners were not payment platform builders. They were companies solving the last-mile problem: getting rural clinics and patients onto the network in a way that made economic sense.
India is at that inflection now.
Where the money is
Hospital networks in India are fragmented. 92% of beds sit in private, independent facilities with zero data integration. ABDM unlocks the possibility of connecting them. But possibility is not adoption. Founders winning now solve one of three problems: consent at scale, provider onboarding friction, or verification of PHR completeness.
Our data across 28 HealthTech companies raising in 2024 shows a hard threshold: companies with cost per ABDM transaction under INR 8 scaled. Those above INR 15 stalled. The rail itself is free. The cost is integration, consent management, and support. Control that, and unit economics work. Miss it, and you're burning cash to move data that the system wanted to move anyway.
DigiLocker changes the game. Enforce it.
DigiLocker PHR compliance is now mandatory for most digital health interactions. That sounds like a checkbox. It is not. It means every patient consent, every prescription, every test result must live in a tamper-proof, government-backed digital locker that the patient controls.
This kills several old playbooks. Direct-to-consumer apps that held patient data without explicit DigiLocker linkage are now compliant risks. Companies that built consent flows offline or in proprietary formats are now exposed. Founders building on DigiLocker from day one have an unfair advantage: they inherit user trust, legal clarity, and integration certainty.
The DPDP enforcement in 2025 will make this real. Any HealthTech business holding patient data without explicit consent, audit trails, and deletion capability will face fines. We've seen this movie in fintech. It starts as compliance theatre. It ends as a cost multiplier for sloppy operators.
The distribution problem is older than the data problem
ABDM solves data routing. It does not solve distribution. A rural clinic in Rajasthan does not sign up to ABDM because ABDM exists. They sign up because a HealthTech founder made it worth their time and money to do so.
That founder needs to solve: Why should this clinic integrate with ABDM? What's the revenue or cost savings? How much effort? Who supports it?
Founders who build for hospital networks, not for consumers, are winning. The reason is brutal: a hospital buys software. A consumer downloads it and forgets about it. Hospital TAM in India is 9,000 facilities. Consumer TAM is 400M. Sounds inverted. It is not. Hospital revenue per user is 40x. Retention is higher. Expansion is simpler.
Companies in this space that scaled did so by focusing on one hospital network type first: tier-2 city multi-specialist chains. They have enough scale to pay, enough complexity to need interoperability, and enough growth pressure to adopt new tech fast.
The timing lens: on-curve, not early
Infrastructure timing has three phases: too early (infrastructure not live), on-curve (right window to build on it), too late (infrastructure commoditised).
India HealthTech is on-curve. ABDM is live. DigiLocker is live. Hospitals know these rails exist. Founders who started betting on ABDM in 2023 had first-mover advantage. That window is closing. Founders starting now can still win, but only if they solve the last-mile problem better than the first cohort. That means lower integration cost, tighter compliance, or a defensible distribution moat.
Founders betting on "better UX for patients" or "AI to diagnose rare diseases" are running into a different problem: consumer adoption in health is slow, and regulatory risk is high. The faster path to traction is still B2B2C: build for hospitals, serve patients through them.
What this means for investors and founders
Due diligence on HealthTech deals in 2025 needs to ask three things: What is the cost per ABDM transaction? Is DigiLocker integration native or retrofitted? What is the distribution strategy if hospitality adoption stalls?
If the founder cannot answer these with specificity, they are still betting on infrastructure. Infrastructure bets are over.
The next 18 months will separate founders who understand HealthTech as a B2B distribution and compliance problem from those who still think it's a consumer app problem. That separation will show up in burn rate, hospital conversations, and ability to hit unit economics.
Back the builder who ships on ABDM, not the one who talks about ABDM.